# EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals, Inc. is a company headquartered in Boston, MA, United States.

## Company overview

- **Legal name:** EPIRUS Biopharmaceuticals, Inc.
- **Former names in filing history:** Zalicus Inc. (2010-09-09 to 2014-07-02); COMBINATORX, INC (2004-12-10 to 2010-08-10); COMBINATORX INC (2002-09-12 to 2004-02-26)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Boston, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001135906

## About

EPIRUS Biopharmaceuticals, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001135906, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2016-03-29, it reported net income of USD -52,188,000; total assets of USD 72,264,000 for the fiscal period ended 2015-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2015 (period ended 2015-12-31)

- **Net income:** -$52.2M (USD -52,188,000)
- **Total assets:** $72.3M (USD 72,264,000)
- **Cash and equivalents:** $31.5M (USD 31,515,000)

### FY2014 (period ended 2014-12-31)

- **Net income:** -$41.8M (USD -41,844,000)
- **Total assets:** $51.4M (USD 51,389,000)
- **Cash and equivalents:** $21.5M (USD 21,462,000)
- **Later filings:** Total assets: shown as originally filed; later filings report different values for the same periods.

### FY2013 (period ended 2013-12-31)

- **Revenue:** $14.7M (USD 14,731,000)
- **Net income:** -$38.6M (USD -38,617,000)
- **Total assets:** $32.1M (USD 32,106,000)
- **Cash and equivalents:** $18.0M (USD 17,958,000)
- **Operating cash flow:** -$29.7M (USD -29,735,000)
- **Later filings:** Net income, Total assets, Cash and equivalents: shown as originally filed; later filings report different values for the same periods.

### FY2012 (period ended 2012-12-31)

- **Revenue:** $12.6M (USD 12,550,000)
- **Net income:** -$44.3M (USD -44,327,000)
- **Total assets:** $61.4M (USD 61,375,000)
- **Cash and equivalents:** $4.5M (USD 4,531,000)
- **Operating cash flow:** -$38.5M (USD -38,489,000)
- **Later filings:** Cash and equivalents: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2016-08-01 — period 2016-07-26 — 8-K
- Form 8-K — filed 2016-07-25 — period 2016-07-13 — 8-K
- Form 8-K — filed 2016-07-01 — period 2016-06-27 — 8-K
- Form 8-K — filed 2016-06-14 — period 2016-06-10 — 8-K
- Form 10-Q — filed 2016-05-10 — period 2016-03-31 — 10-Q
- Form 8-K — filed 2016-05-09 — period 2016-05-06 — 8-K
- Form 10-K/A — filed 2016-04-29 — period 2015-12-31 — 10-K/A
- Form 10-K — filed 2016-03-29 — period 2015-12-31 — 10-K
- Form 8-K — filed 2016-03-15 — period 2016-03-15 — 8-K
- Form 8-K — filed 2016-03-01 — period 2016-02-29 — 8-K
- Form 8-K — filed 2016-02-09 — period 2016-02-09 — 8-K
- Form 10-Q — filed 2015-11-16 — period 2015-09-30 — 10-Q

---

Updated: 2026-10-23T20:06:36Z

Canonical page: https://altss.com/profile/epirus-biopharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology